BioSpace News Archive

Alexion today that the combined interim data from two ongoing open-label studies, VITAL and CL-08, show a 3-year survival estimate of 68% in infants with rapidly progressive lysosomal acid lipase deficiency (LAL-D) treated with Kanuma (sebelipase alfa).1

The share buyback program has been initiated in order to reduce the company’s share capital and to cover obligations under the long-term incentive program.

Neurocrine Biosciences announced today that it will report fourth quarter and year-end 2017 financial results after the Nasdaq market closes on Tuesday, Feb. 13, 2018.

To solve these challenges, Enable has developed a disposable on-body drug delivery device that allows patients to comfortably self-administer high-volume and/or high-viscosity therapeutics.

Thermo Fisher Scientific today announced new laboratory automation technologies designed to streamline workflows, optimize productivity, and speed time to results.

Today, Polaris announced the addition of three senior executives to the firm. Chrisoula Nikidis has been hired as the Canadian Head of Compliance and Ethics Solutions.

The dividend increase will result in a quarterly dividend of $0.57 per share of common stock.

The gross proceeds to Viking from this offering are approximately $63.3M, before deducting underwriting discounts and commissions and other estimated offering expenses.

Verastem today announced the grant of stock options to six new employees to purchase an aggregate of 219,000 shares of Verastem’s common stock.

IQVIA is announcing a novel alliance with the FDA Center for Biologics Evaluation and Research (CBER) to combine advanced analytics and unparalleled information assets to monitor and assist in the evaluation of safety and effectiveness of various CBER-regulated vaccines, blood products and other biologics.